Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of OP-10 in healthy male adults
jRCT2071230132Phase 1Completed
- Sponsor
- Ohara Pharmaceutical Co., Ltd.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of dordaviprone in diffuse midline glioma (DMG) (2 arms), sponsored by Ohara Pharmaceutical Co., Ltd. Primary endpoints: Cmax of OP-10 and AUC(0-t) of OP-10. Started May 2024; status: completed.
02
Drugs
dordaviprone
03
Conditions
diffuse midline glioma (DMG)
Beyond the preview
Go deeper on jRCT2071230132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230132.